TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27194176

Group type: EXPERIMENTAL
Intervention: FOLFOX (fluorouracil-oxaliplatin-folinic acid) combined with concurrent radiotherapy (41.4 Grays)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel combined with concurrent radiotherapy (41.4 Grays)
Number of subjects: 106
Study: 24227768

Group type: EXPERIMENTAL
Intervention: Buprenorphine (32 mg/day i.m.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Morphine (120 mg/day i.m.)
Number of subjects: 7
Study: 22831286

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable puree-based drinks (FVPD) 200 mL daily for 6 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fruit-flavoured control
Number of subjects: 39
Study: 20171695

Group type: EXPERIMENTAL
Intervention: BackStop (experimental group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no antiretropulsion device)
Number of subjects: 68
Study: 17368095

Group type: EXPERIMENTAL
Intervention: Low-level jaw-clenching
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glutamate injection
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 23
Study: 16320148

Group type: EXPERIMENTAL
Intervention: Baseline walking speed reduction (0.10 m/s)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Walking speed increase (0.10 m/s/yr)
Number of subjects: 1388
Study: 12174518

Group type: EXPERIMENTAL
Intervention: Antiplatelet drug triflusal (600 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Anticoagulation for an INR of 2-3
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Combined treatment with anticoagulation (mean INR of 1.85)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Combined treatment with anticoagulation (mean INR of 2.15)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Healthy control subjects (group C)
Number of subjects: 99
Study: 10462363

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 7793997

Group type: EXPERIMENTAL
Intervention: AO-90 (500-750 ml/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Commercial amino acid solution (600-800 ml/day)
Number of subjects: 118
Study: 2358926

Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 130 degrees
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 135 degrees
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 140 degrees
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 145 degrees
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) at 150 degrees
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intact femur with SHS inserted
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stable two-part intertrochanteric fracture reduced with SHS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Four-part fracture with PMF reduced anatomically by a lag screw
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Four-part fracture with PMF rotated 180 degrees and held by a lag screw
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Four-part fracture with PMF discarded
Number of subjects: 24
Study: 393386

Group type: EXPERIMENTAL
Intervention: DTIC at a dose of 200 mg/m2 iv on Days 1‐5 and cis‐dichlorodiammine‐platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks (group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: DTIC at a dose of 200 mg/m2 iv on Days 1‐5 and cis‐dichlorodiammine‐platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks, plus procarbazine at a dose of 75 mg/m2 orally daily on Days 1‐8 and vincristine at a dose of 1.4 mg/m2 iv on Day 1 (group B)
Number of subjects: 29
Study: 30060681

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI) alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI) with 3 weeks of immobilization
Number of subjects: 20
Study: 31262544

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone orally
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 28077214

Group type: EXPERIMENTAL
Intervention: The Incredible Years (IY)
Number of subjects: 387
Study: 25694068

Group type: EXPERIMENTAL
Intervention: Milled flaxseed (30 g/day)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Milled flaxseed (30 g/day) + cholesterol-lowering medications (CLM)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (30 g whole wheat) + cholesterol-lowering medications (CLM)
Number of subjects: 110
Study: 24345206

Group type: EXPERIMENTAL
Intervention: Lurkers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posters
Number of subjects: 0
Study: 21689900

Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fentanyl 50 μg
Number of subjects: 200
Study: 18925978

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) B12 replacement therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal serum B12 levels (>300 pg/mL)
Number of subjects: 28
Study: 17617282

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 14763531

Group type: EXPERIMENTAL
Intervention: Power-operated PMMA vacuum mixing and delivery system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manually powered industry standard
Number of subjects: 0
Study: 11995670

Group type: EXPERIMENTAL
Intervention: FP 200 microg
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: FP 400 microg
Number of subjects: 983

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 983
Study: 9523927

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg, 4 mL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (4 mL of nebulized normal saline)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2039811

Group type: EXPERIMENTAL
Intervention: 49.2 mg pseudoephedrine (ACTIFED)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 1.51 L mineral water
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 1 mg bumetanide
Number of subjects: 1
Study: 6301412

Group type: EXPERIMENTAL
Intervention: 1% delta 9‐tetrahydrocannabinol (delta 9‐THC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vehicle alone (light mineral oil)
Number of subjects: 28
Study: 30663520

Group type: EXPERIMENTAL
Intervention: Subanaesthetic intravenous ketamine infusion
Number of subjects: 30
Study: 29273594

Group type: EXPERIMENTAL
Intervention: Folic acid 0.8 mg combined with enalapril 10 mg
Number of subjects: 8384

Group type: COMPARATOR
Intervention: Enalapril 10 mg alone
Number of subjects: 8384
Study: 26590016

Group type: EXPERIMENTAL
Intervention: 20 mL of normal saline injected into the knee joint of the experimental group.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 40
Study: 25039738

Group type: COMPARATOR
Intervention: Telephone supervision (distant)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: In-person after telephone consultation (immediately available)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: In-person from the beginning of the simulation (direct)
Number of subjects: 53
Study: 22898278

Group type: EXPERIMENTAL
Intervention: Specific sublingual immunotherapy with dermatophagoides farinae drops
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standardized treatment alone (Control)
Number of subjects: 106
Study: 20724562

Group type: EXPERIMENTAL
Intervention: L-arginine (6 g in 500 ml beverage)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 9
Study: 18424200

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethylstarch 130/0.4 (median of 750 ml administered)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethylstarch 130/0.4
Number of subjects: 30
Study: 16186460

Group type: EXPERIMENTAL
Intervention: Recreational physical activities
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Back exercises
Number of subjects: 681
Study: 12540643

Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg orally every 4 hours)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Magnesium sulfate (intravenous according to institutional protocol)
Number of subjects: 1650
Study: 10653212

Group type: EXPERIMENTAL
Intervention: biperiden (4 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: trihexyphenidyl (5 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 9435389

Group type: EXPERIMENTAL
Intervention: Gatellier‐Adams technique (group I)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Kenneth‐Johnson technique (group II)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Crossed canulated screws (group III)
Number of subjects: 3
Study: 8447161

Group type: EXPERIMENTAL
Intervention: Cold-adapted live attenuated vaccine (two doses)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Whole-virus inactivated vaccine (one dose)
Number of subjects: 2
Study: 2876451

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Clomipramine (150 mg/day)
Number of subjects: 150
Study: 31268610

Group type: EXPERIMENTAL
Intervention: Alteplase 2 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Alteplase 1 mg
Number of subjects: 48
Study: 30256784

Group type: EXPERIMENTAL
Intervention: SphygmoCor® CPV device used to assess carotid-femoral PWV
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: SphygmoCor® CPV device used to obtain C‐SBP
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Linear regression analyses for PWV and C‐SBP adjusted for age, sex, and race/ethnicity
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Comparison of PWV in older age groups (> 60 years) with a reference population of hypertensive individuals
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Assessment of associations between PWV or C‐SBP and markers of glucose homeostasis or CKD
Number of subjects: 652
Study: 26833336

Group type: EXPERIMENTAL
Intervention: Ad26.EnvA and Ad35.Env (both administered at a dose of 5 × 10^10 viral particles)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Heterologous regimen of Ad26-Ad35
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Baseline vector immunity
Number of subjects: 217
Study: 24743802

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 22139882

Group type: EXPERIMENTAL
Intervention: Cumulative clinical risk (calculated from pre-HCT neuropsychological risk factors, HCT-related risk factors, and post-HCT complications)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Cumulative clinical risk
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 278
Study: 20975066

Group type: EXPERIMENTAL
Intervention: Sequential high-dose chemotherapy (SHDCT) before myeloablative therapy
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard arm (A) with myeloablative therapy with carmustine, BEAM followed by PBSCT
Number of subjects: 284
Study: 18925347

Group type: EXPERIMENTAL
Intervention: Treatment-naive group
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: One to two prior treatments group
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Three or more prior treatments group
Number of subjects: 1362
Study: 15847747

Group type: EXPERIMENTAL
Intervention: Folic acid 0.2 mg daily for 3 months
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Folic acid 5.2 mg daily for 3 months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 98
Study: 12059949

Group type: EXPERIMENTAL
Intervention: Ritonavir/Indinavir at 400/400 mg BID in combination with two NRTIs (ZDV/3TC, d4T/3TC, or d4T/ddI)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ritonavir/Indinavir at 400/400 mg BID in combination with two NRTIs
Number of subjects: 93
Study: 10686859

Group type: EXPERIMENTAL
Intervention: Enamelon (E)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Crest (C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-fluoride placebo toothpaste (P)
Number of subjects: 18
Study: 7851596

Group type: EXPERIMENTAL
Intervention: Sperm morphology assessment using strict criteria (Tygerberg or Norfolk classification)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Sperm migration ability in vivo under hormonally controlled conditions for the cervical mucus (CM) quality
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Crossed sperm‐CM penetration test performed with CM of patients' partners
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Functional capacity of spermatozoa with normal head morphology
Number of subjects: 163
Study: 1756263

Group type: EXPERIMENTAL
Intervention: Postoperative locoregional and pelvic radiotherapy (RX) and Poly(A).Poly(U) (AU), 60 mg IV once a week for 6 weeks
Number of subjects: 517

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 100 mg/sqm P.O. on days 1‐14, methotrexate 40 mg/sqm IV on day 1 and 8, fluorouracil 600 mg/sqm IV on day 1 and 8; monthly cycle, for 6 months)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Postoperative locoregional and pelvic radiotherapy (RX) and Poly(A).Poly(U) (AU)
Number of subjects: 517
Study: 6802412

Group type: EXPERIMENTAL
Intervention: Three-day course of amoxycillin (25 mg/kg daily)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ten-day course of amoxycillin (25 mg/kg daily)
Number of subjects: 84
Study: 31968351

Group type: EXPERIMENTAL
Intervention: Endobronchial coil implantation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Endobronchial coil implantation (responders)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Endobronchial coil implantation (non-responders)
Number of subjects: 39
Study: 31976336

Group type: EXPERIMENTAL
Intervention: Continuous exercise training (CONT) for 60 minutes at 70% of HRpeak
Number of subjects: 26

Group type: COMPARATOR
Intervention: Interval exercise training (INT) for 60 minutes, alternating 3 minutes at 90% and 50% HRpeak
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both CONT and INT
Number of subjects: 26
Study: 27000142

Group type: EXPERIMENTAL
Intervention: Home-based motor monitoring using wireless motion sensor technology
Number of subjects: 40

Group type: COMPARATOR
Intervention: In-office visits
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home-based motor monitoring
Number of subjects: 40
Study: 27138827

Group type: EXPERIMENTAL
Intervention: Active rTMS over left dorsolateral prefrontal cortex (n=25)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham stimulation (n=22)
Number of subjects: 47
Study: 23419803

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lens treatment
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Younger cohort (<49 days at surgery)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Older cohort (≥ 49 days at surgery)
Number of subjects: 114
Study: 21538069

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 21

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 21
Study: 19142090

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 60
Study: 17537209

Group type: EXPERIMENTAL
Intervention: Defibrillator implant
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 204
Study: 15530197

Group type: EXPERIMENTAL
Intervention: Randomized multi-institutional research protocol studying reintubation rate using three methods for weaning from mechanical ventilation.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Nursing session with five symposia and short oral presentations.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Annual admissions in pediatric intensive care units.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Mortality rate in pediatric intensive care units.
Number of subjects: 217
Study: 11474345

Group type: EXPERIMENTAL
Intervention: C (5 mg x kg(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: E (1 mg x kg(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: C+E
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 24
Study: 10921014

Group type: EXPERIMENTAL
Intervention: Intraperitoneal perfusion chemotherapy (IPPC) with 1 g 5-Fu and 10 mg MMC in warm sterile water, once per day for 6 days.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intravenous infusion of 1 g 5-Fu and 8 mg MMC, once per day for 6 days (Control group).
Number of subjects: 102
Study: 7977595

Group type: EXPERIMENTAL
Intervention: Povidone-iodine 2.5% ophthalmic solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Silver nitrate 1% ophthalmic solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Erythromycin 0.5% ointment
Number of subjects: 100
Study: 2596940

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/d) plus potassium supplement (20 mmol/d)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/d) plus potassium supplement (40 mmol/d)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/d) with triamterene (75 mg/d)
Number of subjects: 447
Study: 31345163

Group type: EXPERIMENTAL
Intervention: Curcumin 1500 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28469045

Group type: EXPERIMENTAL
Intervention: Educational program based on PRECEDE and Trans-Theoretical models, duration: 2 months education and 6 months follow-up.
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Educational program based on PRECEDE and Trans-Theoretical models.
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 344
Study: 25476584

Group type: EXPERIMENTAL
Intervention: Disposable-syringe jet injector (DSJI)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Needle and syringe (NS)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Both DSJI and NS
Number of subjects: 582
Study: 24453924

Group type: EXPERIMENTAL
Intervention: Sulphurous thermal water inhalation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline inhalation
Number of subjects: 40
Study: 21960699

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol 2.5 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol 0.63 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol 1.25 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide
Number of subjects: 70
Study: 19120892

Group type: EXPERIMENTAL
Intervention: rabeprazole, amoxicillin, and GAT for 7 days (RAG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: rabeprazole and amoxicillin (RA)
Number of subjects: 14
Study: 16646120

Group type: EXPERIMENTAL
Intervention: Intensive mental activity (daily memorization of prose passages and demanding mental arithmetic) for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Convenience control group (no intervention)
Number of subjects: 10
Study: 14618551

Group type: EXPERIMENTAL
Intervention: Expressive language impairment
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Receptive language difficulties
Number of subjects: 315
Study: 10826457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1292
Study: 8656385

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 176
Study: 2003591

Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 mg iv bolus)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 19
Study: 7025090

Group type: EXPERIMENTAL
Intervention: Methylglucamine metrizoate (Isopaque Cerebral, 280 mg I/mI)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Metrizamide (Amipaque, 280 mg I/mI)
Number of subjects: 170
Study: 29187584

Group type: EXPERIMENTAL
Intervention: BsAb-5 (bispecific antibody targeting c-MET and CTLA-4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BsAb-5
Number of subjects: 0
Study: 27563831

Group type: EXPERIMENTAL
Intervention: Tailored exercise therapy (20-week individualized, comorbidity-adapted exercise program consisting of aerobic and strength training and training of daily activities)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Current medical care for knee OA (control group)
Number of subjects: 126
Study: 25819948

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention (specifying when, where, and how to act)
Number of subjects: 0
Study: 24209639

Group type: EXPERIMENTAL
Intervention: Fasting for 2 hours (F2) with 200 ml of clear liquids ingested 2 hours before the procedure
Number of subjects: 98

Group type: COMPARATOR
Intervention: Fasting for 8 hours (F8)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Fasting for 2 hours (F2)
Number of subjects: 98
Study: 21468621

Group type: EXPERIMENTAL
Intervention: Stainless steel alloy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nickel-free alloy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Titanium alloy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 19954546

Group type: EXPERIMENTAL
Intervention: Comprehensive exercise group (specific motor relearning and graded activity exercises)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (educational booklet on whiplash)
Number of subjects: 176